Table 1.
Serum pharmacokinetic variables following oral mesalazine dosing.
| Oral dose | 1.2 g day−1 | 2.4 g day−1 | 4.8 g day−1 | |
|---|---|---|---|---|
| Cmax (µg ml−1) | 5ASA | 1.1(0.1- 8.6) | *3.3(0.4-9.2) | *6.0(1.4-4.2) |
| NA5ASA | 2.2(1.4–8.7) | 4.0(0.8–8.5) | *5.9(1.8–10.6) | |
| Cmin (µg ml−1) | 5ASA | 0.03(0-0.2) | *0.2(0.03–1.1) | *1.3(0.4–2.8) |
| NA5ASA | 0.4(0.1–1.0) | *0.8(0.3–2.2) | *2.2(1–3.9) | |
| AUC (µg ml−1 h) | 5ASA | 3.9(0.6–4.3) | *15.4(2.5–66) | *47(8.5–139) |
| NA5ASA | 17.2(7–64) | *31(6–84) | *58(17–117) |
All values expressed as median (range).
*
denotes significant (P < 0.05) between dose differences.